medigraphic.com
ISSN 1561-3038 (Print)

2013, Number 4

<< Back Next >>

Rev Cubana Med Gen Integr 2013; 29 (4)

Pediatric nonalcoholic fatty liver

del Alcázar CM

Language: Spanish
References: 55
Page: 351-368
PDF size: 138.59 Kb.


ABSTRACT

Obesity is a complex multifactor nutritional syndrome or disease with genetic, behavioral and environmental causes, and it is also the most common form of malnutrition in developed and in many developing countries. The NAFL is defined as an anatomical-pathological disease showing over 5 % macrovesicular accumulation of adiposity (triglycerides) in hepatocytes. The spectrum of this disease includes simple steatosis, non-alcoholic steatohepatitis that may bea ccompanied by several levels of fibrosis, and finally cirrhosis in the final stage. The objective of this review was to summarize in a monographic way the most essential aspects of this disease at pediatric ages so that this information may be used by any medical expert.


REFERENCES

  1. Committee on Prevention of Obesity in Children and Youth; Food and Nutrition Board, Board on Health Promotion and Disease Prevention, Institute of Medicine of the National Academies. Preventing Chilhood Obesity. Health in the Balance. Washington, D.C: National Academies Press, 2005.

  2. Mabry IR, Clark SJ, Kemper A, Fraser K, Kileny S, Cabana MD. Variation in establishing a diagnosis of obesity in children. Clin Pediatr. 2005; 44(3):221-7.

  3. Caballero B. The global epidemic of obesity: An overview. Epidemiol Rev. 2007;29:1-5.

  4. Tan FZ, Dong HM, Feng CL, Zeng Q, Dong SX. Study on the relations between overweight, obesity, blood pressure, serum lipids and glucose in schoolchildren of Shijiazhunag. Zhonghua Liu Xing Bing XueZaZhi. 2005;26(8):592-5.

  5. Peña L. Obesidad y Esteatosis/esteatohepatitis. Acta Pediátrica Española. 2011;69 (supl):17.

  6. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of nonalcoholic fatty liver disease in children: a follow-up study for upto 20 years. Gut. 2009;58:153844

  7. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr. 2006;43:413427.

  8. Fishbein MH, Mogren C, Gleason T, Stevens WR. Relationship of Hepatic Steatosis to adipose Tissue Diastribution in Pediatric Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2006;42(1):83-8.

  9. Peña-Quintana L, Colino E, Montedeoca N, González D, Aguiar IA, Saavedra P et al. Obesity and non-alcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2005; 40: 686-7.

  10. Schwimmer JB. Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents Semin Liver Dis 2007;27:312318.

  11. Calderín RO, Prieto M, Cabrera E. Síndrome de insulinorresistencia en niños y adolescentes. Rev. Cubana Endocrinol [revista en la Internet]. 2007 Ago [citado 2010 Mayo 03] ; 18 Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561 - 29532007000200007&lng=es

  12. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641649.

  13. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I, et al. Prevalence of fatty liver in Japanese children andrelationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci. 1995;40: 200209.

  14. Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD):a `growing'problem? J Hepatol. 2007;46:113342.

  15. Pérez F, Benlloch S, Berenguer M, Beltrán B, Berenguer J. Esteato-hepatitis no alcohólica: consideraciones fisiopatológicas, clínicas y terapéuticas. Rev Esp Enferm Dig. 2004;96(9):1-22.

  16. Ciba I, Widhalm K. The association between non-alcoholic fattyliver disease and insulin resistance in 20 obese children andadolescents. Acta Paediatr. 2007;96:109112.

  17. Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, et al. NAFLD in children: a prospective clinicalpathological study and effect of lifestyle advice. Hepatology. 2006; 44:458465.

  18. Wasada T., Kasahara T., Wada J., Jimba S., Fujimaki R., Nakagami T., et al. Hepatic steatosis rather than visceral adiposity is more closely associated whith insulin resistance in the early stage of obesity. Metabolism. 2008; 57(7):980-5.

  19. Ardigo D, Numeroso F, Valtuena S, Franzini L, Piatti PM, Monti L, et al. Hyperinsulinemia predicts hepatic fatconten in healthy individuals with normal transaminase concentrations. Metabolism. 2005;54(12):1566-70.

  20. Louthan MV, Barve S, Mc Clain CJ, Joshi-Barve S. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr. 2005; 147:835-8

  21. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002; 16: 663-78.

  22. Pessayre D. Role of mitochondria in non-alcoholic fatty liverdisease. J Gastroenterol Hepatol. 2007;(Suppl 1): S20S27.

  23. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004;30:121-38.

  24. Ekstedt M, Franze´n LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44:865873.

  25. Nagata K, Suzuki H, Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J ToxicolSci. 2007; 32:453468.

  26. Cheung AT, Wang J, Ree D, Kolls JK, Bryer-Ash M. Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. Diabetes. 2000;49:810819.

  27. Louthan MV, Barve S, McClain CJ, Joshi-Barve S. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr. 2005;147:835838.

  28. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, et al. Highsensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007;42:573582.

  29. Turcotte LP, Fisher JS. Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. PhysTher. 2008; 88: 127996.

  30. Stefan M, Nicholls RD. What have rare genetic syndromes taught us about the pathophysiology of the common forms of obesity? Curr Diab Rep. 2004;4:143150.

  31. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ,Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology.2005; 41: 1313-21.

  32. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123: 745750.

  33. Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol. 1991;43: 26-31.

  34. Erdogmus B, Tamer A, Buyukkaya R, Yazici B, Buyukkaya A, Korkut E et al. Portal vein hemodynamics in patients with nonalcoholic fatty liver disease. J Exp Med. 2008;215: 8993.

  35. Dietrich CF, Lee JH, Gottschalk R, Herrmann G, Sarrazin C, Caspary WF et al. Hepatic and portal vein flow pattern in correlation with intrahepatic fat deposition and liver histology in patients with chronic hepatitis C. AJR Am J Roentgenol. 1998;171:437-43.

  36. Sagi R, Reif S, Neuman G, Webb M, Phillip M, Shalitin S. Nonalcoholic fatty liver disease in overweight children and adolescents. ActaPaediatr 2007;96:1209-13.

  37. Pacheco Torres L, Piñeiro Lamas R, Fragoso Arbelo T, Valdés Alonso MC. Hígado graso no alcohólico en niños obesos. Rev Cubana de Pediatr [revista en la Internet]. 2006 Mar [citado 2010 mayo 20]; 78(1): Disponible en: http://scielo.sld.cu/scielo.phpscript=sc¡arttex&pid=S003453120060001&ing=es.

  38. SchwenzerNF, Springer F, Schraml C, Stefan N, MachannJ,Schick F. Noninvasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51:433-445.

  39. Longo R, Ricci C, Masutti F, Vidimari R, Croce´ LS, Bercich L et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computedtomography. Invest Radiol. 1993;28:297-302.

  40. Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239:105-112.

  41. Tobari M, Hashimoto E, Yatsuji S, Torii N, Shiratori K. Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography. Intern Med. 2009;48:739-46.

  42. Carter-Kent C, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC et al. Nonalcoholic steatohepatitis in children: a multicenter clinic pathological study. Hepatology. 2009;50:11131120.

  43. Chrysanthos NV, Papatheodoridis GV, Savvas S, Kafiri G, Petraki K, Manesis EK et al. Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol. 2006;18:389-96.

  44. Abdo AA, Al Swat K, Azzam N, Ahmed S, Al Faleh F. Of three noninvasive laboratory variables to predict significant fibrosis and cirrhosis in patients with chronic hepatitis C in Saudi Arabia. Ann Saudi Med 2007;27:89-93.

  45. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M et al. A novel diagnostic biomarker panel forobesity-related nonalcoholic steatohepatitis (NASH). Obes Surg.2008;18:1430-37.

  46. Garg A, Simha V. Update on dislypidemia. J Clin Endocrinol. Met. 2007; 92(5):1581-89.

  47. McPherson R, Frohlich J, Fodor G. Canadian Cardiovascular Society position statement recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006;22: 913-27.

  48. Le NA, Walter MFF. The role of hypertriglyceridemia in atherosclerosis. Cu-rrent Atheroes Rep. 2007; 9(2):110-115.

  49. Yuan G, Al-Shali K, Hegele RA. Hypertriglyceridemia: its etiology, effects and current treatment. CMAJ. 2007;176(8):1113-20.

  50. Kohen-Avramoglu R, Theriault A, Adeli K. Emergence of themetabolicsyn-drome in childhood: an epidemiological overview and mechanistic link to dyslipemia. Clinical Biochemistry.2003;36:413-20.

  51. Srinivasan SR, Myers M, Berenson GS. Predictability of childhood adiposity and insulin for developing insulin resistance syndrome in young adulthood: the Bogalusa Heart Study. Diabetes. 2002;51:204-9.

  52. Roberts E. Nonalcoholic steatohepatitis in children. Curr Gastroenterol Rep. 2003; 5: 253-9.

  53. Schwimmer JB,Middleton MS, Deutsch R, Lavine JE. A phase2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005; 21: 871-9.

  54. Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr. 2004; 38: 48-55.

  55. Nanda K. Non-alcoholic steatohepatitis in children. Pediatr Transplant. 2004; 8: 613-8.




2020     |     www.medigraphic.com